Adult Immunization in Cardiovascular Disease

Definition

The evidence-based practice of vaccinating adults with cardiovascular disease (CVD) against respiratory and systemic infections as a component of secondary cardiovascular prevention. Patients with CVD are at higher risk of adverse outcomes from infections such as influenza, pneumococcal pneumonia, COVID-19, RSV, and herpes zoster, and vaccination reduces morbidity, mortality, and cardiovascular events in this population.

Key Concepts

General Evidence Framework

• CVD patients face higher infection risk and more severe outcomes from respiratory infections than the general population sources/immunization-acc-2025 (very high)
• Four lines of evidence support vaccination in CVD: (1) elevated infection severity risk; (2) RCT evidence; (3) consistent observational data; (4) adverse effects far outweighed by benefit sources/immunization-acc-2025 (very high)

Influenza Vaccine

• Influenza infection increases acute MI risk 6-fold sources/immunization-acc-2025 (very high)
• Annual vaccination recommended for all CVD patients; nasal vaccine NOT recommended for adults >50 years
• AHA/ACC 2023 Chronic Coronary Disease guideline: Class I, Level A for annual influenza vaccination to reduce CV morbidity, CV mortality, and all-cause death
• AHA/ACC/HFSA 2022 Heart Failure guideline: Class 2a, Level B-NR for respiratory vaccination to reduce mortality
• Meta-analysis of 6 RCTs (n=6,734): MACE RR 0.64 (95% CI 0.48–0.96); follow-up 7.9 months; benefit more pronounced post-ACS than in stable disease sources/immunization-acc-2025 (very high)
• IAMI trial (n=2,571 post-acute MI): influenza vaccine reduced all-cause death/MI/stent thrombosis at 12 months by 28% (HR 0.72; 95% CI 0.52–0.99) — terminated early due to COVID-19 pandemic sources/immunization-acc-2025 (very high)
• HF-specific RCT (n=5,129): primary endpoint neutral (HR 0.93; P=0.30); but significant benefits on all-cause hospitalisation and pneumonia during influenza season sources/immunization-acc-2025 (very high)
• Enhanced formulations (high-dose, recombinant, adjuvanted) preferred for older adults
• Guillain-Barré syndrome risk: ~1–2 cases/million influenza vaccine doses (extremely rare)

Pneumococcal Vaccine

• Pneumococcal pneumonia causes ~225,000 adult hospitalisations/year in the US; 10–20% fatality rate sources/immunization-acc-2025 (very high)
• Recommended for: adults ≥50 years (all); adults 19–49 years with CHD, HF, cardiomyopathies, CLD, smoking, DM — Hypertension alone does NOT qualify
• Preferred agents: PCV20 or PCV21 (single dose, no subsequent vaccination required); PCV15 requires subsequent PPSV23
• Can be given concurrently with influenza, COVID-19, and RSV vaccines
• Dutch RCT: PCV — 75% efficacy vs vaccine-type invasive pneumococcal disease; 45% vs pneumococcal pneumonia sources/immunization-acc-2025 (very high)

COVID-19 Vaccine

• CVD patients 3× more likely to develop severe COVID-19 sources/immunization-acc-2025 (very high)
• Benefits include reduced MI, pericarditis/myocarditis, stroke, AF, and long-COVID from COVID-19 infection
• mRNA vaccine myocarditis: 1–19 cases/million doses after first 2 doses; predominantly young males; almost universally benign with complete recovery sources/immunization-acc-2025 (very high)
• 2024-2025 CDC ACIP recommendations:
  • No prior vaccination: 2-dose initial series (Day 0 + 6 months minimum)
  • Adults <65 years: at least 1 vaccination with 2024-2025 formulation
  • Adults ≥65 years or immunocompromised: at least 2 vaccinations with 2024-2025 formulation (6 months apart)
• AHA/ACC 2023 Chronic Coronary Artery Disease guideline: Class 1 for COVID-19 vaccination per public health guidelines
• AHA/ACC/HFSA 2022 Heart Failure guideline: Class 2A for respiratory vaccination

RSV Vaccine

• RSV causes 60,000–160,000 adult hospitalisations/year in adults ≥65 years in the US sources/immunization-acc-2025 (very high)
• Chronic HF, CAD, COPD, DM among highest-risk groups for severe RSV disease
• CDC recommendations: adults ≥75 years (all); adults 50–74 years with chronic medical conditions — one-time vaccination, NOT annual
• 3 licensed vaccines as of June 2025: 2 protein subunit vaccines (≥50 years); 1 mRNA vaccine (≥60 years)
• Efficacy: ~80% vs lower respiratory tract disease year 1; ~70% year 2
• Protein subunit vaccines: small Guillain-Barré syndrome risk (7–9 cases/million doses)

Zoster (Shingles) Vaccine

• Herpes zoster induces inflammatory state → increased stroke and MI risk; CVD patients more susceptible to zoster sources/immunization-acc-2025 (very high)
• South Korean observational study (n>1 million): zoster vaccination reduced MI, stroke, HF, and arrhythmia — benefit lasted 8 years post-vaccination sources/immunization-acc-2025 (very high)
• Patients with CAD receive equivalent or greater vaccine effectiveness than other chronic disease populations
• CDC recommendation: All adults ≥50 years — 2 doses of recombinant zoster vaccine (Shingrix), 2–6 months apart

Implementation and Hesitancy

• Cardiovascular-focused messaging is the most effective communication strategy to improve vaccination rates (NUDGE-FLU trial, n>960,000) sources/immunization-acc-2025 (very high)
• Framing vaccine as "reserved for you" improved influenza and COVID-19 vaccination uptake (US health system study)
• Cardiologists are key vaccination advocates, particularly for post-hospitalisation/post-MI patients before primary care re-engagement
• All CDC-recommended vaccines must be covered under the Affordable Care Act without out-of-pocket cost
• Multiple vaccines can be co-administered (EXCEPT PCV15 + PPSV23, which must be separated)

Contradictions / Open Questions

• HF evidence gap: Influenza vaccine benefit in HF is less robust than in stable CAD/post-MI (one RCT neutral for primary endpoint); the mechanism by which vaccination benefits CVD patients (direct vs infection-reduction mediated) remains uncertain
• RSV reimmunisation: timing and frequency of RSV booster vaccination are not yet established; guidance pending
• Zoster CV benefit — mechanism: observational data on cardiovascular benefit of zoster vaccine requires RCT confirmation; whether benefit is mediated purely through infection prevention or has independent anti-inflammatory effects is unknown
• COVID-19 vaccination frequency: annual vaccination recommendations may evolve as COVID-19 epidemiology continues to change; relevance of maintaining annual updates for CVD patients will need reassessment
• mRNA vs protein RSV vaccine GBS risk: GBS signal observed only with protein subunit RSV vaccines; insufficient mRNA RSV vaccine data due to fewer doses administered

Connections

• Related to entities/Heart-Failure — vaccination as secondary prevention in HF
• Related to entities/Chronic-Coronary-Disease — Class I influenza + COVID-19 guideline recommendations
• Related to concepts/Influenza-and-MI — 6-fold MI risk with influenza infection
• Related to concepts/Vaccine-Hesitancy-CVD — implementation strategies
• Related to entities/Atrial-Fibrillation — COVID-19 vaccination reduces AF risk from COVID-19 infection
• Related to entities/Hypertension — note: hypertension alone does NOT qualify for early pneumococcal vaccination

Sources

• sources/immunization-acc-2025 — primary source for all content on this page